Filter Publications By:


The Expert Review of Vaccines, 2007; 6(5):747-759.

Immunostimulatory DNA as a Vaccine Adjuvant.

Debbie Higgins, Jason D Marshal, Paula Traquina, Gary Van Nest and Brian Livingston.


Immunological Reviews, 2008; 223:271-283.

Development of TLR inhibitors for the treatment of autoimmune diseases.

Frank J. Barrat and Robert L. Coffman.


Immunity, 2010; 33(4):492-503.

Vaccine adjuvants: putting innate immunity to work.

Coffman, RL, Sher A, Seder RA.


Sci. Transl. Med., 2011; 3(93):93rv2.

Assessing the safety of adjuvanted vaccines.

Ahmed SS, Plotkin SA, Black S, Coffman RL.


Vaccine. 2013 Nov 4;31(46):5306-13.

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.


Vaccine. 2013 Nov 4;31(46):5300-5.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age.

Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT.


Nat. Biotechnol. 2000; 18: 509-514.

Immunostimulatory DNA-based Vaccines Induce Cytotoxic Lymphocyte Activity by a T Helper Cell-independent Mechanism.

Cho, H.J., K. Takabayashi, P.M. Cheng, M.D. Nguyen, M. Corr, S. Tuck, and E. Raz.


Blood, 2005. 105(2):489-495.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkins lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Friedberg, J.W., H. Kim, M. McCauley, E.M. Hessel, P. Sims, D.C. Fisher, L.M. Nadler, R.L. Coffman, and A.S. Freedman.


Clin Cancer Res. 2008;14(17):5626-34.

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM.


Br J Haematol. 2009;146(3):282-91. PMCID: PMC2747261

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS.